Abstract
HMG-CoA reductase inhibitors (statins) are among the most widely used hypolypemizing drugs with a pleiotropic activity. Numerous clinical trials have demonstrated that statins can have a significant effect in the prevention of cardiovascular diseases in the general population. In patients with renal failure, this drug preserves the hypolypemizing efficacy found in the general population without increasing their unwanted side-effects. The re-analysis of data from epidemiological studies conducted on the general population has confirmed that statins provide cardiovascular protection also in subjects with renal failure. These data have been partly confirmed by the findings made by 4D (Die Deutsche Diabetes Dialyse Studie) and Alert studies, conducted on diabetic patients on dialysis and patients with renal transplants, respectively. The results of other studies, such as AURORA, SHARP, REnal and Vascular End stage Disease, and ESPLANADE, clearly indicate that statins prevent cardiovascular disease in patients with renal insufficiency, just as they do in the general population.
Keywords: Cardiovascular disease (CVD), HMG-Coenzyme A reductase Inhibitors, Dialysis, transplantation, nephropathic patients
Cardiovascular & Hematological Disorders-Drug Targets
Title: Statins in the Prevention of Cardiovascular Events in Patients with Renal Failure
Volume: 7 Issue: 1
Author(s): Michele Buemi, Fulvio Floccari, Lorena Nostro, Susanna Campo, Chiara Caccamo, Alessio Sturiale, Carmela Aloisi, Maria Stella Giacobbe and Nicola Frisina
Affiliation:
Keywords: Cardiovascular disease (CVD), HMG-Coenzyme A reductase Inhibitors, Dialysis, transplantation, nephropathic patients
Abstract: HMG-CoA reductase inhibitors (statins) are among the most widely used hypolypemizing drugs with a pleiotropic activity. Numerous clinical trials have demonstrated that statins can have a significant effect in the prevention of cardiovascular diseases in the general population. In patients with renal failure, this drug preserves the hypolypemizing efficacy found in the general population without increasing their unwanted side-effects. The re-analysis of data from epidemiological studies conducted on the general population has confirmed that statins provide cardiovascular protection also in subjects with renal failure. These data have been partly confirmed by the findings made by 4D (Die Deutsche Diabetes Dialyse Studie) and Alert studies, conducted on diabetic patients on dialysis and patients with renal transplants, respectively. The results of other studies, such as AURORA, SHARP, REnal and Vascular End stage Disease, and ESPLANADE, clearly indicate that statins prevent cardiovascular disease in patients with renal insufficiency, just as they do in the general population.
Export Options
About this article
Cite this article as:
Buemi Michele, Floccari Fulvio, Nostro Lorena, Campo Susanna, Caccamo Chiara, Sturiale Alessio, Aloisi Carmela, Stella Giacobbe Maria and Frisina Nicola, Statins in the Prevention of Cardiovascular Events in Patients with Renal Failure, Cardiovascular & Hematological Disorders-Drug Targets 2007; 7 (1) . https://dx.doi.org/10.2174/187152907780059119
DOI https://dx.doi.org/10.2174/187152907780059119 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytochrome P450 2C8 and Drug Metabolism
Current Topics in Medicinal Chemistry Vitamin E-Related Inhibition of Monocyte 5-Lipoxygenase and Cardiovascular Outcome in Maintenance Hemodialysis Patients
Recent Patents on Inflammation & Allergy Drug Discovery Novel Insights Into Lp(a) Physiology and Pathogenicity: More Questions Than Answers?
Cardiovascular & Hematological Disorders-Drug Targets Selective Serotonin Re-Uptake Inhibitors and Hyponatremia in Acutely Medically-Ill Inpatients
Current Drug Safety Clinical Perspectives on Antidepressant Drug Development: A Critical Discussion
Current Pharmaceutical Design The Therapeutic Potential of Induced Pluripotent Stem Cells After Stroke: Evidence from Rodent Models
Current Stem Cell Research & Therapy Therapeutic Value of Statins for Vascular Remodeling
Current Vascular Pharmacology Effect of Gender on Main Clinical Chemistry Parameters in Aged Rats
Current Aging Science A Yeast Extract High in Bioactive Peptides has a Blood-Pressure Lowering Effect in Hypertensive Model
Current Medicinal Chemistry Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism Parental Hypertension and Cardiovascular Reactivity in Young Adults
Vascular Disease Prevention (Discontinued) Hypertension and Diabetes: Emphasis on the Renin-Angiotensin System in Atherosclerosis
Current Hypertension Reviews Inotropic Therapies in Asphyxiated Neonates: The Clinical and Laboratory Facts
Current Pediatric Reviews Cerebral White Matter Lesions, Risk of Stroke and Cerebrovascular Protection with Angiotensin Receptor Blockers
Current Drug Therapy Pharmacogenomics of Osteoporosis
Current Pharmacogenomics Mechanisms of Medial Arterial Calcification in Diabetes
Current Pharmaceutical Design Genomics and Natural Products: Role of Bioinformatics and Recent Patents
Recent Patents on Biotechnology Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Current Pharmaceutical Design Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Recent Developments in the Treatment of Alcoholic Chronic Pancreatitis
Current Drug Abuse Reviews